BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 10463541)

  • 1. Validation of bioassays for quality control.
    Lansky D
    Dev Biol Stand; 1999; 97():157-68. PubMed ID: 10463541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioassays for the characterisation and control of therapeutic cytokines; determination of potency.
    Thorpe R; Wadhwa M; Page C; Mire-Sluis A
    Dev Biol Stand; 1999; 97():61-71. PubMed ID: 10463531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virus assay methods: accuracy and validation.
    Darling AJ; Boose JA; Spaltro J
    Biologicals; 1998 Jun; 26(2):105-10. PubMed ID: 9811514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parametric and non-parametric prediction intervals based phase II control charts for repeated bioassay data.
    Hothorn LA; Gerhard D; Hofmann M
    Biologicals; 2009 Oct; 37(5):323-30. PubMed ID: 19647449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of cytokines by bioassays: theory and application.
    Meager A
    Methods; 2006 Apr; 38(4):237-52. PubMed ID: 16481200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of a quantitative cell-based bioassay for comparing the pharmacokinetic profiles of two recombinant erythropoietic proteins in serum.
    Wei X; Grill DS; Heatherington AC; Swanson SJ; Gupta S
    J Pharm Biomed Anal; 2007 Jan; 43(2):666-76. PubMed ID: 16971087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strip-plot designs, mixed models, and comparisons between linear and non-linear models for microtitre plate bioassays.
    Lansky D
    Dev Biol (Basel); 2002; 107():11-23. PubMed ID: 12079185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical validity of bioassays.
    Heath AB
    Dev Biol Stand; 1999; 97():151-6. PubMed ID: 10463540
    [No Abstract]   [Full Text] [Related]  

  • 9. Validation of assays for use with combination vaccines.
    Klein J; Capen R; Mancinelli R; Robinett R; Pietrobon PJ; Quinn J; Schofield T
    Biologicals; 1999 Mar; 27(1):35-41. PubMed ID: 10441401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ensuring quality of in vitro alternative test methods: Current practice.
    Rispin A; Stitzel K; Harbell J; Klausner M
    Regul Toxicol Pharmacol; 2006 Jul; 45(2):97-103. PubMed ID: 16644076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Different Estimation Methods for Accuracy and Precision in Biological Assay Validation.
    Yu B; Yang H
    PDA J Pharm Sci Technol; 2017; 71(4):297-305. PubMed ID: 28416644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Setting specifications for potency assays--basic principles.
    Mire-Sluis AR
    Dev Biol (Basel); 2002; 107():107-15. PubMed ID: 12079184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro potency assay for hepatitis A vaccines: development of a unique economical test.
    Poirier B; Morgeaux S; Variot P; Fuchs F
    Biologicals; 2000 Dec; 28(4):247-56. PubMed ID: 11237361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of bioassays for the characterisation and control of biological therapeutic products produced by biotechnology.
    Thorpe R; Wadhwa M; Mire-Sluis A
    Dev Biol Stand; 1997; 91():79-88. PubMed ID: 9413686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine bioassays: an overview.
    House RV
    Dev Biol Stand; 1999; 97():13-9. PubMed ID: 10463526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing bioassay variability by identifying sources of variation and controlling key parameters in assay protocol.
    Ren S; Frymier PD
    Chemosphere; 2004 Oct; 57(2):81-90. PubMed ID: 15356920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological standardization of cytokines and growth factors.
    Mire-Sluis AR; Padilla A; Das RG
    Dev Biol Stand; 1999; 97():171-6. PubMed ID: 10463542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.
    Bertolotto A; Sala A; Caldano M; Capobianco M; Malucchi S; Marnetto F; Gilli F
    J Immunol Methods; 2007 Apr; 321(1-2):19-31. PubMed ID: 17335844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of a candidate in vitro potency assay for inactivated Newcastle disease vaccines.
    Maas R; Komen M; Oei H; Claassen I
    Dev Biol (Basel); 2002; 111():163-9. PubMed ID: 12678237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of the COSTIM bioassay for dendritic cell potency.
    Shankar G; Fourrier MS; Grevenkamp MA; Lodge PA
    J Pharm Biomed Anal; 2004 Oct; 36(2):285-94. PubMed ID: 15496321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.